PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development lifecycle with the U.S.
Abingworth, the international investment group dedicated to life sciences, today announced that it has seeded GammaDelta Therapeutics Ltd, a new immunotherapy company. GammaDelta Therapeutics also received support from three organisations, Cancer Research Technology (CRT), King’s College London and the Francis Crick Institute. The company is being incubated at Abingworth’s London
“I am very pleased that Reinhard has accepted the role of CFO of the Group, and I am also proud to welcome Magnus Lundbäck back to Getinge. Both have comprehensive experience of the Group and in-depth expertise
in their respective fields,” Joacim Lindoff, Acting President and CEO of Getinge.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals Inc. announced today that it has completed a $5
million Series A financing to support its upcoming Phase II trial in
patients with Amyotrophic Lateral Sclerosis (ALS). Morningside Venture
led the financing and was joined by the ALS Investment Fund and former
Genzyme CEO Henri Termeer, as well as new
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative
medicine company with a focus on pluripotent stem cell technology, and
its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today
announced that Cell Cure has been awarded a new grant for 2016 of 8.4
million shekels (approximately $2.2 million) from
By Vivien Diniz
It’s a merger of equals between Quintiles and IMS Health.
By Vivien Diniz
Five life science companies made it onto this year’s TSX Venture 50 list. Read on to find out which ones made the cut and how they performed in 2015.
The 2nd annual Biotech and Money London congress is a two-day congress providing the education, strategies and solutions life science companies need to enable more effective funding, investment, business planning and partnering within their business.
Australia’s life science sector often flies under the radar. However, at least one industry player is looking to put a stop to that.
Boston Business Journal reported that Boston now hosts the heaviest concentration of life science companies in the world. Interestingly, however, the state is between third and eighth in terms of total life science job growth.
Q1 is now over, and to mark the occasion, Life Science Investing News has assembled the articles that got the most traffic during the period. Unsurprisingly, readers were most interested in hearing about trends for 2015, though stock picks were also a key topic.
Patient Home Monitoring and Theralase Technologies are two life science companies that made the 2015 TSX Venture Top 50 list.
Some market participants are wondering if Johnson & Johnson has entered the Ebola vaccine race too late.
Next Gen Metals (CSE:N,OTCMKTS:NXTTF,FWB:M5BN) is a diversified public company focused on finance and investments in the Medical Marijuana, industrial hemp and alternative medicine industries in North America.
Saama Technologies Inc. announced yesterday the successful implementation of a “comprehensive data and analytics platform” for life science companies. It is called Saama Sales Operations Solution for Life Science and is intended to help during the commercialization phase of drug development.